Skip to main content
SpringerLink
Log in

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC (68Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively.

Methods

A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by 68Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients.

Results

A total of 38 metastases were treated. The involved sites were pelvic bone (n = 16), pelvic lymph nodes (n = 11), paraaortic lymph nodes (n = 6), ribs (n = 3) and vertebral body (n = 2). The median PSA prior to RT was 1.1 ng/mL (range 0.1–29.0 ng/mL). A median dose of 43.5 Gy (range 30–64 Gy) was delivered by IMRT-IGRT in 12–27 fractions. At a median follow-up of 7 months (range 2–17 months), 19 patients (83%) were in remission. Four patients (17%) developed distant recurrences. The actuarial 1-year LC, PFS and OS rates were 100, 51 (95% CI 8–83%) and 100%. Univariate analysis demonstrated a statistically significantly better PFS in CS patients as compared to CR patients (1-year PFS 67 vs. 0%, p < 0.01). One patient experienced grade 2 acute gastrointestinal toxicity. Grade 3 or more toxicity events were not observed.

Conclusions

By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that 68Ga PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer. Validation by randomized trials is eagerly awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  PubMed  Google Scholar 

  2. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.

    Article  Google Scholar 

  3. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74:297–305.

    Article  CAS  PubMed  Google Scholar 

  4. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:1384–90.

    Article  CAS  Google Scholar 

  5. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2881–6.

    Article  CAS  Google Scholar 

  6. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol Esp. 2011;35:565–79.

    Article  CAS  PubMed  Google Scholar 

  7. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.

    Article  PubMed  Google Scholar 

  8. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27–32.

    Article  PubMed  Google Scholar 

  9. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50:1617–27.

    Article  PubMed  Google Scholar 

  10. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–34.

    Article  PubMed  Google Scholar 

  11. Engert A, Raemaekers J. Treatment of early-stage Hodgkin lymphoma. Semin Hematol. 2016;53:165–70.

    Article  PubMed  Google Scholar 

  12. Onal C, Reyhan M, Guler OC, Yapar AF. Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1336–42.

    Article  CAS  PubMed  Google Scholar 

  13. Madsen PH, Holdgaard PC, Christensen JB, Hoilund-Carlsen PF. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2084–97.

    Article  CAS  PubMed  Google Scholar 

  14. Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013;38:e342–5.

    Article  PubMed  Google Scholar 

  15. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, et al. New clinical indications for F/C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2016;70:161–75.

    Article  PubMed  Google Scholar 

  16. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.

    Article  CAS  PubMed  Google Scholar 

  18. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2015;56:668–74.

    Google Scholar 

  19. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34–41.

    Article  CAS  PubMed  Google Scholar 

  20. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of 68 Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2016;44:92–101.

    Article  PubMed  Google Scholar 

  21. Deutschmann H, Kametriser G, Steininger P, Scherer P, Scholler H, Gaisberger C, et al. First clinical release of an online, adaptive, aperture-based image-guided radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional rotations of the prostate. Int J Radiat Oncol Biol Phys. 2012;83:1624–32.

    Article  PubMed  Google Scholar 

  22. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.

    Article  PubMed  Google Scholar 

  24. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030–6.

    CAS  PubMed  Google Scholar 

  25. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997;57:4687–91.

    CAS  PubMed  Google Scholar 

  26. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701.

    Article  CAS  PubMed  Google Scholar 

  27. Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11:73.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Shakespeare TP. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiat Oncol. 2015;10:233.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, et al. 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: early efficacy after primary therapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2016;192:431–9.

    Article  Google Scholar 

Download references

Acknowledgements

The results of this study were presented in the 22nd National Oncology Congress 19–23 April 2017, Antalya, Turkey, and was awarded the “Best Oral Presentation Award”. Also, it was represented as a poster presentation in ASCO-2017 Genitourinary Cancer Symposium 16–18 February 2017, Orlando, USA.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, 61080, Turkey

    O. C. Guler

  2. Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium

    B. Engels, R. Van den Begin, T. Gevaert & M. de Ridder

  3. Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey

    C. Onal

  4. Department of Nuclear Medicine, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium

    H. Everaert

Authors
  1. O. C. Guler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Engels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Everaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Van den Begin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Gevaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. de Ridder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. C. Guler.

Ethics declarations

Conflict of interest

All authors have stated that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The present work is a retrospective analysis of clinical data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guler, O.C., Engels, B., Onal, C. et al. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol 20, 484–490 (2018). https://doi.org/10.1007/s12094-017-1736-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1736-9

Keywords

Search

Navigation